Walgreens and three other pharmacy chains are suing drugmaker Bausch Health, its subsidiaries, and a separate generic drugmaker for allegedly colluding on a deal that allowed the brand-name companies to maintain a longer monopoly of the diabetes drug Glumetza.
According to Reuters, the alleged deal resulted in those companies jacking up the price of the drug from US$350 to more than US$3,000 for a 30-day supply.
The lawsuit, filed on Monday, December 2, alleges that Assertio and Lupin struck a deal with units of Bausch to delay the entry of their generic versions of Glumetza and allowed the companies to “maintain a monopoly” in the sale of the branded drug and its generic copies.
Albertson Companies and Kroger were among the other defendants.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.